Diet sodas might not raise diabetes risk

November 16, 2016

Nov 16: Drinking colas and other sugary drinks is tied to an increased risk of so-called pre-diabetes, a precursor to full-blown disease, but diet soda is not, a recent study suggests.

dietPrevious studies on the link between diet sodas and diabetes have been mixed; some research pointing to a potential connection has suggested this relationship may be explained at least in part by soda drinkers being overweight or obese.

In the current study, however, adults who routinely consumed at least one can of soda or other sugar-sweetened beverages a day were 46 percent more likely to develop elevated blood sugar levels than people who rarely or never drink cola.

“Emphasis should be placed on substituting sugar-sweetened beverages with water, unsweetened teas, or coffee,” said senior study author Nicola McKeown, a nutrition researcher at Tufts University in Boston.

“For daily consumers of sugary drinks, kicking the habit may be a difficult challenge, and incorporating an occasional diet soda, while increasing fluids from other sources, may be the best strategy to ultimately remove sugar-sweetened beverages from the diet,” McKeown added by email.

Globally, about one in nine adults have diabetes, and the disease will be the seventh leading cause of death by 2030, according to the World Health Organization. Most of these people have Type 2, or adult-onset, diabetes, which happens when the body can't properly use or make enough of the hormone insulin to convert blood sugar into energy.

People with blood sugar levels that are slightly elevated, but not high enough for a diabetes diagnosis, are sometimes described as having “pre-diabetes” because many will go on to develop diabetes. In the current study, researchers examined data collected on 1,685 middle-aged adults over about 14 years.

At the start of the study, none of the participants had diabetes or pre-diabetes. They were 52 years old on average and typically overweight.

Participants completed questionnaires detailing what they ate and drank during the study period. Sugar-sweetened beverages were defined as colas and other carbonated beverages, as well as drinks such as lemonade and fruit punch. This didn’t include fruit juice.

People who drank the most sodas – typically around six 12-ounce cans a week – had a much greater risk of developing elevated blood sugar levels than other participants after adjusting for factors such as age, gender and weight, researchers report in the Journal of Nutrition.

Higher consumption of soda and other sugar-sweetened beverages was also associated with insulin resistance, a reduced ability to respond to the hormone insulin that is another risk factor for developing diabetes.

Even after accounting for changes in weight and other aspects of diet, the relationships between sugar-sweetened beverages and these metabolic risk factors for diabetes persisted.

Diet soda intake—defined as low-calorie cola or other carbonated low-calorie beverages— was not associated with elevated blood sugar or insulin resistance.

The study doesn’t prove soda or sugary drinks cause diabetes.

Another limitation of the study is that participants may not be representative of a typical U.S. adult, the authors note. People in the study were mostly white, middle aged and more likely to be women. They also tended not to be as overweight or thick around the middle as many U.S. adults, the authors point out.

Because pre-diabetic elevated blood sugar can often be reversed before it advances to full-blown disease, the findings suggest it makes sense for people to avoid regular sodas to minimize their risk of developing diabetes, the researchers conclude.

“Sugar sweetened beverages have been shown to increase weight gain and risk of diabetes – including prediabetes,” Laura Rosella, a public health researcher at the University of Toronto who wasn’t involved in the study, said by email.

The current study findings add to a large body of evidence suggesting that the sugar and calories in soda can contribute to the risk of obesity and diabetes, noted Dr. Robert Cohen, a researcher at the University of Cincinnati College of Medicine who wasn’t involved in the study.

“I wouldn’t necessarily seek out diet drinks but the choice of non-calorie containing diet drinks is not associated with further insulin resistance or pre-diabetes in the way that calorie containing drinks are,” Cohen said by email.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 17,2020

Leading physicians are celebrating a small dose of good news that arrived Tuesday about dexamethasone, a cheap and widely used steroid shown to be able to save lives among COVID-19 patients, but also cautioning against releasing study results by press release during a global health emergency, like in the case of the latest dexamethasone study by University of Oxford.

"It will be great news if dexamethasone, a cheap steroid, really does cut deaths by one-third in ventilated patients with COVID19, but after all the retractions and walk backs, it is unacceptable to tout study results by press release without releasing the paper", Atul Gawande, surgeon and CEO of Haven Healthcare, tweeted.

"Bottom line is, good news," Dr. Fauci, America's foremost infectious diseases expert told a US newswire on Tuesday, soon after the dexamethasone results were announced in the UK.

Fauci, who has long championed the therapeutics-first view said that dexamethasone is a "significant improvement" in the available therapeutic options currently available.

On Medical Twitter and Facebook, doctors broadly agree that dexamethasone use aligns well with the way COVID19 attacks the body's immune system. Fauci said the results in the Oxford study make "perfect sense" in that context.

"We should see the number of people who actually survive go up, if the study holds up," virologist and epidemiologist Dr. Joseph Fair told a television network.

Global coronavirus cases crossed 8 million on Tuesday. In the US, Texas and Florida are facing a new wave of cases after lifting lockdown orders earlier than medical experts recommended. Amidst the relentless graph upwards, the dexamethasone study results injected hope for better survival rates among those most seriously ill.

World Health Organization chief scientist Soumya Swaminathan welcomed the results from the randomised control trial.

Dr Eugene Gu, Founder and CEO of CoolQuit tweeted that he is "genuinely impressed" with the UK dexamethasone trial. This may be a "game changer", he wrote.

"There's no conflict of interest as dexamethasone is a generic steroid. The mechanism of action makes sense because steroids can reduce cytokine storms and overactive immune systems that makes COVID-19 so deadly. The number needed to treat is 8 ventilated patients which is great."

The Oxford study found that dexamethasone reduced deaths by 35 percent in patients who needed treatment with breathing machines and by 20 percent in those only needing supplemental oxygen. Dexamethasone was one of 5 drugs studied in a large clinical trial in the United Kingdom named RECOVERY, short for Randomised Evaluation of COVID-19 Therapy.

Peter Horby, chief investigator of the University of Oxford clinical trial, said dexamethasone is the first drug to be shown to improve survival in COVID-19. Details of the study have not been released. The trial organisers said they made their announcement via a news release because of "the public health importance of these results." According to Horby's public comments, there was a lot of initial resistance to studying steroids.

During the study, 2,104 patients were randomly selected to be given 6 milligrams of dexamethasone once a day (either by mouth or by intravenous injection) for 10 days. That group was compared with 4,321 patients who received the usual care alone.

Researchers estimated that dexamethasone would prevent one death for every eight patients treated while on ventilators and one for every 25 patients on extra oxygen alone.

UK experts have called the study results a breakthrough in the fight against the virus. The researchers have promised they would publish the results soon.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
April 14,2020

There is no evidence that the Bacille Calmette-Guerin (BCG) vaccine, which is primarily used against tuberculosis, protects people against infection with the novel coronavirus, the World Health Organization (WHO) said.

The WHO therefore didn't recommend BCG vaccination for the prevention of COVID-19 in the absence of evidence, according to its daily situation report on Monday, Xinhua news agency reported.

"There is experimental evidence from both animal and human studies that the BCG vaccine has non-specific effects on the immune system. These effects have not been well characterized and their clinical relevance remains unknown," WHO stated.

Two clinical trials addressing the question are underway, and WHO will evaluate the evidence when it is available, it noted.

BCG vaccination prevents severe forms of tuberculosis in children and diversion of local supplies may result in an increase of disease and deaths from the tuberculosis, it warned.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 27,2020

After admitting that the world may have a COVID-19 vaccine within one year or even a few months earlier, the World Health Organisation (WHO) on Friday said that UK-based AstraZeneca is leading the vaccine race while US-based pharmaceutical major Moderna is not far behind.

WHO Chief Scientist Soumya Swaminathan stated that the AstraZeneca's coronavirus vaccine candidate is the most advanced vaccine currently in terms of development.

"I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials," she told the media.

AstraZeneca's Covid-19 vaccine candidate developed by researchers from the Oxford University will likely provide protection against the disease for one year, the British drug maker's CEO told Belgian radio station Bel RTL this month.

The Oxford University last month announced the start of a Phase II/III UK trial of the vaccine, named AZD1222 (formerly known as ChAdOx1 nCoV-19), in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries.

Last week, Swaminathan had said that nearly 2 billion doses of the COVID-19 vaccine would be ready by the end of next year.

Addressing the media from Geneva, she said that "at the moment, we do not have a proven vaccine but if we are lucky, there will be one or two successful candidates before the end of this year" and 2 billion doses by the end of next year.

Scientists predict that the world may have a COVID-19 vaccine within one year or even a few months earlier, said the Director-General of the World Health Organization even as he underlined the importance of global cooperation to develop, manufacture and distribute the vaccines.

However, making the vaccine available and distributing it to all will be a challenge and will require political will, WHO chief Tedros Adhanom Ghebreyesus said on Thursday during a meeting with the European Parliament's Committee for Environment, Public Health and Food Safety.

One option would be to give the vaccine only to those who are most vulnerable to the virus.

There are currently over 100 COVID-19 vaccine candidates in various stages of development.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.